跳到正文
原文
Nature Medicine·· 8 天前AI 评分60

世界卫生组织发布儿童和青少年肥胖治疗指南

Young people with obesity deserve better care

AI 导读

世界卫生组织发布了针对儿童和青少年肥胖治疗的首份指南,不推荐在儿童中使用药物治疗,仅在青少年中作为最后手段。指南指出,肥胖治疗证据不足,需更多研究填补空白。

正文

The evidence available to support the treatment of obesity in children and adolescents is insufficient and requires rapid improvement.

On 7 October 2026, the World Health Organization released its first guidelines for the treatment of obesity among children under 10 years of age and adolescents (10–19 years of age). The guidelines do not recommend pharmacological treatment such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) in children. In adolescents, the guidelines recommend pharmaceutical intervention only after exhaustion of other treatment options. The evidence bases for pharmacotherapy and more traditional weight-loss interventions (such as exercise or diet) are rated as low and very low, respectively. The guidelines, although useful and much needed, highlight a litany of evidence gaps that need filling.

Addressing obesity in children and adolescents is an unmet need. Although the rates of obesity are slowing in adults with access to drugs such as GLP-1RAs, no such trend has been seen in children. In 1990, for instance, 8% of adolescents worldwide were overweight. In 2024, that figure had increased to 20%.

Obesity in youth is likely to persist into adulthood. For instance, 70% of adolescents with obesity are still with obesity at 30 years of age1. Obesity is associated with long-term conditions such as chronic kidney diseases and type 2 diabetes. Such chronic illnesses can take many years to manifest, but obesity also poses a risk to children in the immediate term. Children with obesity are at greater risk of poor oral health, asthma, hypertension and even pediatric autoimmune disorders than are children without obesity. They also face stigma that leads to depression and decreased educational attainment2.

The rising trends of young people with obesity can be explained by increasingly sedentary lifestyles, combined with increased uptake of high-fat and high-sugar foods. Subtler causes of childhood obesity include lower socioeconomic status3 and having parents with obesity4. It is this complexity of interactions that causes common-sense recommendations to fail. Physical activity for a child with obesity is possible only if that child lives in an area where they can easily exercise. The ‘sanitized’ environments of randomized controlled trials, including investigating personal providing advice, are unlikely to be replicable in real world conditions, such as youths who live in dense urban environments with limited exercise space and high air pollution. Future exercise research must be better modeled on where young people actually are.

Dietary intervention studies face similar hurdles. Dietary advice is useful only if the individual, or their parents or carers, can afford or have access to healthy food. Government programs, such as prescribing food vouchers, can support those struggling to afford healthy food and have been found to have health benefits5. These benefits, however, have not yet been investigated for children, who are seldom responsible for the food they eat. Interventions for tackling obesity in children must also incorporate how to empower those responsible for a child’s diet (whether they are parents, guardians or schoolteachers).

Given the impact of GLP-1RAs in the treatment of adults with obesity, it is sensible to consider the possibility that these drugs may offer benefits for children. However, the evidence base for (or against) their use in this group is lagging behind. For adolescents, for whom their conditional use has been recommended, the evidence for GLP-1RAs also remains limited. It will not be sufficient to only collect information on efficacy in younger people; it is possible that safety signals differ between this population and adults. Long-term follow-up will be needed to ensure that pharmacotherapy, for instance, does not interfere with the development that occurs during puberty.

Current evidence suggests that cessation of GLP-1RAs leads to weight regain in adults6, which means that to treat obesity, GLP-1RAs will probably be lifelong medications. Therefore, starting GLP-1RA medication in childhood could lead to that child’s remaining on the medication for life. As that child grows, they may wish to stop taking the medication, for instance, owing to gastrointestinal side effects or simply an inability to access the medication. Healthcare systems will need to develop strategies for managing patients who are ending their use of GLP-1RAs in adulthood, possibly without ever having had to manage their weight without pharmacological assistance.

There is also the danger that access to GLP-1RAs without medical oversight could lead to their abuse among young people. Those investigating eating disorders and body dysmorphia would need to consider the effect that normalization of GLP-1RA use in children would have on these conditions.

There is an urgent need to address obesity in children and adolescents. Children find themselves in a complex obesogenic environment that prioritizes high-fat ultra-processed food over healthier alternatives. It is also an environment whose construction they had little say in. Young people at the very least deserve treatment options informed by evidence that fully takes into account the complexity of the world they are growing up in.

来源:Nature Medicine · nature.com